

PRODUCT INFORMATION

PACAP (6-38) (human, chicken, mouse, ovine, porcine, rat) (trifluoroacetate salt)
Item No. 24554

Formal Name: L-phenylalanyl-L-threonyl-L- α -aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-arginyl-L-lysyl-L-glutamyl-L-methionyl-L-alanyl-L-valyl-L-lysyl-L-lysyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-valyl-L-leucylglycyl-L-lysyl-L-arginyl-L-tyrosyl-L-lysyl-L-glutamyl-L-arginyl-L-valyl-L-lysyl-L-asparagyl-L-lysineamide, trifluoroacetate salt
Synonym: Pituitary Adenylate Cyclase-activating Peptide (6-38)

MF: $C_{182}H_{300}N_{56}O_{45}S \cdot XCF_3COOH$


FW: 4,024.8

Purity: $\geq 95\%$

Supplied as: A lyophilized powder

Storage: $-20^{\circ}C$

Stability: ≥ 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

PACAP (6-38) (human, chicken, mouse, ovine, porcine, rat) (trifluoroacetate salt) is supplied as a lyophilized powder. A stock solution may be made by dissolving the PACAP (6-38) (human, chicken, mouse, ovine, porcine, rat) (trifluoroacetate salt) in water. The solubility of PACAP (6-38) (human, chicken, mouse, ovine, porcine, rat) (trifluoroacetate salt) in water is approximately 1 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

Pituitary adenylate cyclase-activating peptide (PACAP) (6-38) is a PACAP receptor antagonist with IC_{50} values of 30, 600, and 40 nM, respectively for rat PAC_1 , rat $VPAC_1$, and human $VPAC_2$ recombinant receptors expressed in CHO cells.¹ It binds to PACAP receptors in rat brain membrane ($IC_{50} = 39.14$ nM) and to SH-SY5Y and SK-N-MC human neuroblastoma and T47D human breast cancer cells (IC_{50} s = 2.9, 129, and 227 nM, respectively).^{2,3} *In vivo*, in newborn pigs, PACAP (6-38) (10 μ M) inhibits vasodilation of pial arterioles induced by PACAP (1-38) (Item No. 24770), the full-length peptide.⁴ It also inhibits decreased food intake and reduced body weight in rats induced by cocaine- and amphetamine-regulated transcript peptides (CARTp) following intracerebroventricular administration of 0.3-3 mol per animal doses.⁵

References

- Gourlet, P., Vandermeers, A., Vandermeers-Piret, M.-C., *et al.* *Eur. J. Pharmacol.* **287**(1), 7-11 (1995).
- Moro, O., Wakita, K., Ohnuma, M., *et al.* *J. Biol. Chem.* **274**(33), 23103-23110 (1999).
- Eggenberger, M., Born, W., Zimmermann, U., *et al.* *Neuropeptides* **33**(2), 107-114 (1999).
- Lenti, L., Domoki, F., Kis, D., *et al.* *Brain Res.* **1165**, 81-88 (2007).
- Burgos, J.R., Iresjö, B.-M., and Smedh, U. *PLoS One* **8**(8):e72347, (2013).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/17/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM